Phaseline

Companies › Optinose US

Optinose US: clinical trials, targets and expected readouts

1 active drug program in 7 registered trials: 3 Phase 2, 2 Phase 3, 2 Phase 4; Immunology, Other, Respiratory; next expected readout Mar 2028.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Fluticasone Propionate (OPN-375)
Glucocorticoid receptor agonist
NR3C1Phase 3Chronic Rhinosinusitis Without Nasal Polyps; Allergic Rhinitis; Healthy; Chronic Cough …Mar 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07415278Fluticasone Propionate (OPN-375)Phase 4Allergic RhinitisImmunologyOct 2023
NCT02476825Fluticasone Propionate (OPN-375)Phase 4HealthyOtherOct 2026
NCT05275686Fluticasone Propionate (OPN-375)Phase 2Eustachian Tube DysfunctionOtherJun 2027
NCT07582549Fluticasone Propionate (OPN-375)Phase 3Chronic CoughOtherDec 2027
NCT03002389Fluticasone Propionate (OPN-375)Phase 2Chronic Obstructive Pulmonary DiseaseRespiratoryJan 2028
NCT06850805Fluticasone Propionate (OPN-375)Phase 3Chronic Rhinosinusitis Without Nasal PolypsRespiratoryMar 2028
NCT03742414Fluticasone Propionate (OPN-375)Phase 2Eczema, InfantileImmunologyMay 2028

Targets

NR3C1 (1)

Companies with the same targets

Corcept Therapeutics Oticara Australia AstraZeneca Eupraxia Pharmaceuticals Alimera Sciences Laboratorios Sophia S.A de C.V. Santhera Pharmaceuticals Pop Test Oncology Pacira Pharmaceuticals Tiohundra

Companies built like this

Oticara Australia Zhejiang Wenda Pharma Technology ReAlta Life Sciences Tiohundra Abivax

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.